Trial Profile
Efficacy and safety of Mylotarg (gemtuzumab ozogamicin) as salvage treatment in children with refractory or relapsed acute myeloid leukemia.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2018
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 27 Mar 2009 New trial record